Compared to other forms of mutation, CBF‐AML (AML1/ETO or CBFβ‐MYH11) has a relatively good prognosis: about 75% of AML‐M5 individuals achieved CR following the induction therapy, compared with only 43.2% of those in all patients. The gene discussed is RUNX1; the disease is acute myeloid leukemia.